End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
35.5 NZD | -1.39% | +1.25% | 0.00% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The stock, which is currently worth 2024 to 0.57 times its sales, is clearly overvalued in comparison with peers.
- Sales forecast by analysts have been recently revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- The firm trades with high earnings multiples: 22.15 times its 2024 earnings per share.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 4.12B | B- | ||
+15.21% | 70.09B | C+ | ||
-2.19% | 24.01B | C+ | ||
+8.13% | 8.32B | B | ||
-18.28% | 8.23B | B- | ||
0.00% | 8.08B | C | ||
+19.12% | 4.41B | B+ | ||
-3.16% | 3.88B | B | ||
+23.97% | 3.71B | C+ | ||
+8.07% | 3.39B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EBO Stock
- Ratings EBOS Group Limited